ClinicalTrials.gg
RecruitingNCT07583212Updated Jul 13, 2026

Phase I Study of HRS-1635 in B-cell Malignancies

A Phase 1 interventional study of HRS-1635 in B-cell Malignancy, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-1635 in participants with B-cell malignancy.

02

Conditions studied

  • B-cell Malignancy
03

In context

Lead sponsor

Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old;
  2. (ECOG) performance status score of 0-1;
  3. Expected survival time ≥ 12 weeks;
  4. or cytologically confirmed B-cell malignant tumor;
  5. Females of and male participants whose partners are females of childbearing potential must agree to adopt adequate and effective measures during the study period. Female participants must not be breastfeeding;
  6. Participants voluntarily enroll in the study, sign the form, with good compliance and willingness to cooperate with follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  1. Tumor infiltration of the central nervous system;
  2. A history of other malignant tumors (excluding the study disease) within 2 years prior to the first administration of the study drug;
  3. A history of hematopoietic stem cell transplantation or solid organ transplantation;
  4. Positive for surface antigen (HBsAg) at screening with evidence of viral replication confirmed by HBV-DNA test;
  5. Positive for virus antibody (HCV-Ab) at screening with evidence of viral replication confirmed by HCV-RNA test;
  6. Positive for (HIV) antigen/antibody test at screening;
  7. History of major surgery or severe trauma within 28 days prior to the first administration of the study drug;
  8. Presence of severe cardiovascular disease.;
  9. Persistent alcohol or drug abuse;
  10. Inability to take oral medication, or presence of severe gastrointestinal dysfunctional diseases, or history of surgery with severe impact on gastrointestinal function.
  11. Pregnant or lactating females.
  12. Concurrent participation in other interventional clinical trials, or an interval of less than 1 month between the signing date of the form and the last administration of the study drug in the previous clinical trial;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    HRS-1635

    Drug: HRS-1635

Interventions

  • DrugHRS-1635

    HRS-1635

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events.

    Time frame: approximately 2 year

  2. DLT(Dose-limiting toxicity)

    Time frame: approximately 23 days

Secondary outcomes

  1. Peak Concentration (Cmax)

    Time frame: 15 weeks after treatment initiation

  2. Area Under the Curve (AUC0-t, AUC0-inf)

    Time frame: 15 weeks after treatment initiation

  3. Half-life (t1/2)

    Time frame: 15 weeks after treatment initiation

  4. Apparent Clearance (CL/F)

    Time frame: 15 weeks after treatment initiation

  5. Apparent Volume of Distribution (Vz/F)

    Time frame: 15 weeks after treatment initiation.

  6. Relative bioavaliability of HRS-1635 in the fed versus fasted state.

    Time frame: 48 hours post-dose

  7. Objective Response Rate (ORR)

    Time frame: approximately 2 year

  8. Time to Response (TTR)

    Time frame: approximately 2 year

  9. Duration of Response (DoR)

    Time frame: approximately 2 year

  10. Progression-Free Survival (PFS)

    Time frame: approximately 2 year

  11. Overall Survival (OS)

    Time frame: approximately 2 year

  12. Time to Peak Concentration (Tmax)

    Time frame: 15 weeks after treatment initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Oct 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 13, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07583212
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Jun 30, 2026
Primary completion
Oct 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

Bin Hu
Contact
bin.hu5@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion